ARCHIVES OF TOXICOLOGY is a prestigious journal published by Springer Heidelberg, dedicated to advancing research in the field of toxicology and related disciplines. With a distinguished history dating back to 1930, this journal has continuously provided vital insights and groundbreaking studies, making it a cornerstone in the areas of health, toxicology, and medicine. Recognized for its high impact, it occupies a top-ranking position in Scopus, with remarkable quartile placements in 2023, categorizing it as Q1 in Health, Toxicology and Mutagenesis, and Q1 in Medicine (Miscellaneous). The journal highlights critical research and innovative methodologies, appealing to a diverse audience of researchers, professionals, and students committed to understanding the complexities of toxic substances and their implications for public health and environmental safety. The journal does not currently offer open access, allowing for a more traditional but rigorous peer-review process that ensures the quality and integrity of every published article. Join the global discourse in toxicological science with ARCHIVES OF TOXICOLOGY, where every contribution furthers the understanding of safety and toxicity in our world.

Chemical Research in Toxicology is a premier journal published by the American Chemical Society, dedicated to advancing the understanding of toxicological effects associated with chemical substances. Since its inception in 1988, this esteemed journal has maintained a robust impact factor, ranking in the Q1 quartile for both Medicine (miscellaneous) and Toxicology as of 2023, reflecting its significance and influence in the fields of pharmacology and toxicology. With an impressive Scopus ranking at #16 out of 133 in the Toxicology category, it serves as a vital resource for researchers, professionals, and students seeking cutting-edge insights and scholarly articles that bridge the gap between chemistry and toxicological science. Although not an open-access publication, it continues to provide comprehensive analyses and original research that inform safe chemical practices and regulatory policies, further enhancing its role in public health and safety.

Chemical Biology Letters is a prominent academic journal dedicated to the evolving field of biochemistry and its applications in medical and clinical contexts. Published by ScienceIn Publications, this journal serves as a vital platform for researchers, professionals, and students alike, showcasing cutting-edge findings and innovations that drive forward our understanding of chemical interactions in biological systems. With its scope ranging from molecular biology to clinical biochemistry, Chemical Biology Letters is committed to advancing knowledge and fostering collaboration within the scientific community. Recognized for its quality, the journal is categorized in Q4 for Biochemistry and Molecular Biology fields, while achieving notably higher ranks in Medical Biochemistry, reflecting its significant contributions to the discipline. Aiming to remain accessible to a diverse audience, the journal is published in open access format, inviting researchers worldwide to explore and share invaluable insights. Established in 2014, it continues to grow in impact and relevance, paving the way for advancements in both theoretical and applied research within the realm of chemical biology.

Chemical Biology & Drug Design, an esteemed publication by WILEY, serves as a vital platform for the dissemination of pioneering research in the interdisciplinary fields of biochemistry, drug discovery, molecular medicine, organic chemistry, and pharmacology. With a dedicated commitment to advancing the understanding of chemical interactions and drug development, this journal not only fosters innovation but also bridges the gap between theoretical research and practical applications. It boasts an impressive impact factor and is recognized in the 2023 category quartiles as Q3 in Biochemistry and Molecular Medicine, and Q2 in Drug Discovery, Organic Chemistry, and Pharmacology, indicating its relevance and influence in these crucial areas. The journal’s rankings across various Scopus categories further solidify its position as a reputable resource for researchers, professionals, and students striving to stay at the forefront of medicinal chemistry and drug design. While primarily traditional access-based, the journal's evolving scope from 2006 to 2024 ensures an ongoing contribution to essential scientific dialogue, making it an indispensable read for those committed to advancing health sciences.

NATURAL PRODUCT RESEARCH is a distinguished journal published by Taylor & Francis Ltd, dedicated to advancing the field of natural product science through the dissemination of high-quality research. Established in 2003, this journal serves as a pivotal platform for scholars in Analytical Chemistry, Biochemistry, Organic Chemistry, and Plant Science, boasting an impressive categorization including Q2 in Plant Science and Q3 in the other disciplines for 2023. With a current Scopus ranking that highlights its significance within various scientific communities, NATURAL PRODUCT RESEARCH reflects the complexities and innovations associated with natural compounds and their applications. Researchers, professionals, and students will find valuable insights and breakthroughs that contribute to the understanding of bioactive compounds and their roles in health and environmental sustainability. Access options are available, ensuring that the latest findings are accessible to a global audience. As this journal continues to publish until 2024, it remains an essential resource for those at the forefront of natural product research.

MOLECULAR DIVERSITY, published by Springer, stands as a pivotal platform within the fields of chemistry, biology, and pharmacology since its inception in 1995. This esteemed journal aims to foster interdisciplinary research and innovation, particularly in areas such as catalysis, drug discovery, inorganic and organic chemistry, and molecular biology. With a diverse scope that reflects contemporary scientific challenges, it has been recognized for its significant contributions, boasting commendable Scopus rankings and an impact factor that underscores its relevance in critical fields. Although not an open access journal, MOLECULAR DIVERSITY continues to influence and engage researchers, professionals, and students alike by providing a forum for high-quality peer-reviewed articles and cutting-edge research findings. As it converges years of scientific dynamism from 1995 to 2024, this journal remains vital for those advancing the frontiers of molecular science and engineering.

ChemMedChem is a leading international journal published by WILEY-V C H VERLAG GMBH in the United Kingdom, specializing in the interdisciplinary fields of medicinal chemistry and drug discovery. With a commendable impact factor that places it in the Q1 quartile for Organic Chemistry and among the Q2 ranks in several other key categories including Biochemistry, Molecular Medicine, and Pharmacology, ChemMedChem serves as a vital platform for the dissemination of innovative research and transformative insights in the development of pharmaceutical agents. Since its inception in 2006, this journal has been at the forefront of advancing knowledge that bridges the gap between fundamental research and practical applications in medicine, making it an essential resource for researchers, professionals, and students alike. Although it currently does not offer Open Access options, the journal ensures high-quality peer-reviewed content that engages its audience and fosters collaborative scientific discourse.

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, published by TAYLOR & FRANCIS INC, serves as a pivotal platform for the dissemination of original research in the fields of biochemistry, molecular biology, and structural biology. With an ISSN of 0739-1102 and an E-ISSN of 1538-0254, this esteemed journal has garnered attention for its rigorous peer-review process and commitment to high-quality scientific inquiry since its inception in 1981. Ranking in the Q2 quartile for miscellaneous medicine and the Q3 quartile for both molecular and structural biology, it consistently demonstrates a significant impact within its specialties, evidenced by a high Scopus ranking. Researchers, professionals, and students are encouraged to engage with cutting-edge studies addressing the complex interactions and dynamics of biomolecules, making this journal a vital resource for advancing knowledge in the biological sciences. Although it does not offer open access options, its valuable contributions are vital for the ongoing discourse within the scientific community.

Molbank is an open-access journal published by MDPI, dedicated to the fields of Biochemistry, Organic Chemistry, and Physical and Theoretical Chemistry. Established in 2002, this journal has served as a vital platform for the dissemination of research findings, where researchers and professionals share original articles focusing on molecular chemistry, synthesis, and related studies. With a commitment to open access, Molbank enables global access to scientific knowledge, fostering collaboration and innovation among scientists. While currently categorized in the fourth quartile for its field rankings, it provides a unique opportunity for emerging scholars to contribute to and engage with the scientific community. The journal is based in Switzerland, operating from its office at ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND, and continues to attract submissions until 2024. Researchers, students, and professionals looking to expand their knowledge and participate in the dialogue of current molecular chemistry can benefit significantly from engaging with the content published in Molbank.

Letters in Drug Design & Discovery is an esteemed journal dedicated to advancing the fields of Drug Discovery and Molecular Medicine. Published by Bentham Science Publishers, this journal offers a platform for the dissemination of innovative research and advanced methodologies, enhancing collaboration among researchers and professionals in pharmaceutical sciences. Despite its current Q4 ranking in Drug Discovery and Molecular Medicine and Q3 in Pharmaceutical Science for 2023, the journal is committed to improving its presence in the academic community by providing quality, peer-reviewed publications that cover various aspects of drug design and discovery, including novel therapeutic approaches and methodologies. With a focus on both foundational and cutting-edge research from around the globe, Letters in Drug Design & Discovery is pivotal for those seeking to stay abreast of developments in drug development and molecular research. Researchers are encouraged to submit their work, engage with the burgeoning field, and contribute to the ongoing dialogue driven by this journal, which spans the years from 2005 to 2024. While the journal does not currently offer open access, its contributions remain accessible to a wide range of academic and professional audiences.